Article Text

Download PDFPDF
COPD: how many asthmatics does it take to make an impact?
  1. Jo Congleton, DTB Associate Editor
  1. Brighton and Sussex University Hospitals NHS Trust, East Sussex, UK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Inhaled corticosteroids (ICS) have had an interesting and evolving course in regard to their use in chronic obstructive pulmonary disease (COPD). They have moved from not being on the menu at all in the 1970s, trialled with great hope in the 1980s, widespread adoption in the 1990s, before falling under a shadow in the 2000s because of concerns over increased risk of pneumonia. However, the place of ICS in the management of COPD is now the subject of renewed interest. Although the initial ICS COPD trials that assessed rate of decline in lung function by measuring forced expiratory volume in 1 second as the primary outcome measure were negative, manufacturers persisted in looking for a role for ICS in COPD. Their efforts paid off with trials of ICS in …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.